Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis

Fig. 3

Survival analysis of CCA patients stratified for HER2 gene amplification

Displayed are the survival curves for the HER2-negative patients (red curve) and the HER2-positive patients (blue curve) (n = 361). Median survival was nominally lower in the HER2-negative group (3.8 years) than in the HER2-positive group (6.9 years), though not statistically significant (p = 0.471)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us